American Journal of Clinical Dermatology

, Volume 15, Issue 6, pp 537–542 | Cite as

Isotretinoin Use and Celiac Disease: A Population-Based Cross-Sectional Study

  • Benjamin Lebwohl
  • Anders Sundström
  • Bana Jabri
  • Sonia S. Kupfer
  • Peter H. R. Green
  • Jonas F. Ludvigsson
Original Research Article

Abstract

Background and aim

Isotretinoin, a vitamin A analogue, can promote a pro-inflammatory milieu in the small intestine in response to dietary antigens. We hypothesized that oral isotretinoin exposure would increase the risk of celiac disease (CD).

Methods

We contacted all 28 pathology departments in Sweden, and through biopsy reports identified 26,739 individuals with CD. We then compared the prevalence of ever using oral isotretinoin to the prevalence in 134,277 matched controls through conditional logistic regression. Data on isotretinoin exposure were obtained from the national Swedish Prescribed Drug Registry. As the only indication for isotretinoin use in Sweden is acne, we also examined its relationship to CD. Data on acne were obtained from the Swedish Patient Registry.

Results

Ninety-three individuals with CD (0.35 %) and 378 matched controls (0.28 %) had a prescription of isotretinoin. This corresponded to an odds ratio (OR) of 1.22 [95 % confidence interval (CI) 0.97–1.54]. Risk estimates were similar in men and women, and when we restricted our data to individuals diagnosed after the start of the Prescribed Drug Registry. Restricting our analyses to individuals diagnosed aged 12–45 years did not influence the risk estimates (OR 1.38, 95 % CI 0.97–1.97). Meanwhile, having a diagnosis of acne was positively associated with CD (OR 1.34, 95 % CI 1.20–1.51).

Conclusions

This study found no association between isotretinoin use and CD, but a small excess risk of CD in patients with a diagnosis of acne.

Notes

Acknowledgments

BL was funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1 TR000040. JFL was supported by grants from the Swedish Society of Medicine, the Swedish Research Council—Medicine (522-2A09-195), and the Swedish Celiac Society.

Competing interests

Dr. Lebwohl: The author declares that he has no conflict of interest. Dr. Sundström: The author declares that he has no conflict of interest. Dr. Jabri: The author declares that she has no conflict of interest. Dr. Kupfer: The author declares that she has no conflict of interest. Dr. Green: The author declares that he has no conflict of interest. Dr. Ludvigsson: The author declares that he has no conflict of interest.

Details of ethics approval

This project (2006/633-31/4) was approved by the Research Ethics Committee of the Karolinska Institute, Sweden, on June 14, 2006.

Authors’ contributions

International Committee of Medical Journal Editors (ICMJE) criteria for authorship read and met: BL, AS, BJ, SSK, PG, and JFL. Agree with the manuscript’s results and conclusions: BL, AS, BJ, SSK, PG, and JFL. Designed the experiments/the study: BL and JFL. Collected data: JFL. Analyzed the data: BL. Wrote the first draft of the paper: BL and JFL. Contributed to study design, interpretation of data and writing: AS and PG. Interpretation of data; approved the final version of the manuscript: BL, AS, BJ, SSK, PG, and JFL. Responsible for data integrity: JFL. Obtained funding: JFL.

Supplementary material

40257_2014_90_MOESM1_ESM.doc (84 kb)
Supplementary material 1 (DOC 84 kb)

References

  1. 1.
    Maki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence of celiac disease among children in Finland. N Engl J Med. 2003;348(25):2517–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107(10):1538–44; quiz 7, 45.Google Scholar
  3. 3.
    Elfstrom P, Granath F, Ekstrom Smedby K, Montgomery SM, Askling J, Ekbom A, et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst. 20112;103(5):436–44.Google Scholar
  4. 4.
    Ludvigsson JF, Olsson T, Ekbom A, Montgomery SM. A population-based study of coeliac disease, neurodegenerative and neuroinflammatory diseases. Aliment Pharmacol Ther. 2007;25(11):1317–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Collin P, Reunala T, Pukkala E, Laippala P, Keyrilainen O, Pasternack A. Coeliac disease—associated disorders and survival. Gut. 1994;35(9):1215–8.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Sollid LM. Molecular basis of celiac disease. Annu Rev Immunol. 2000;18:53–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Akobeng AK, Ramanan AV, Buchan I, Heller RF. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child. 2006;91(1):39–43.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118(2):511–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56(Pt 12):1669–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Ou G, Hedberg M, Horstedt P, Baranov V, Forsberg G, Drobni M, et al. Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol. 2009;104(12):3058–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanson LA. Breastfeeding provides passive and likely long-lasting active immunity. Ann Allergy Asthma Immunol. 1998;81(6):523–33; quiz 33–4, 37.Google Scholar
  12. 12.
    Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685–98.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Mention JJ, Ben Ahmed M, Begue B, Barbe U, Verkarre V, Asnafi V, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125(3):730–45.Google Scholar
  14. 14.
    DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature. 2011;471(7337):220–4.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2010;105(9):1986–93.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case–control study. Am J Gastroenterol. 2009;104(11):2774–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case–control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology. 1992;102(1):330–54.PubMedGoogle Scholar
  19. 19.
    Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Ludvigsson JF, Brandt L, Montgomery SM, Granath F, Ekbom A. Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol. 2009;9(1):19.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35.Google Scholar
  22. 22.
    Ludvigsson JF, Brandt L, Montgomery SM. Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa. BMC Gastroenterol. 2009;9:57.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Pais WP, Duerksen DR, Pettigrew NM, Bernstein CN. How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc. 2008;67(7):1082–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Ludvigsson JF, Montgomery SM, Ekbom A, Brandt L, Granath F. Small-intestinal histopathology and mortality risk in celiac disease. JAMA. 2009;302(11):1171–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Olen O, Bihagen E, Rasmussen F, Ludvigsson JF. Socioeconomic position and education in patients with coeliac disease. Dig Liver Dis. 2012 Feb 14.Google Scholar
  26. 26.
    Olen O, Bihagen E, Rasmussen F, Ludvigsson JF. Socioeconomic position and education in patients with coeliac disease. Dig Liver Dis. 2012;44(6):471–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317(5835):256–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Stephensen CB, Livingston KA. Vitamin supplements and vaccines: maximize benefits, evaluate potential risks. Am J Clin Nutr. 2009;90(3):457–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Hall JA, Cannons JL, Grainger JR, Dos Santos LM, Hand TW, Naik S, et al. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity. 2011;34(3):435–47.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol. 2006;101(7):1569–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Sundstrom A, Alfredsson L, Sjolin-Forsberg G, Gerden B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ. 2010;341:c5812.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Bowe WP, Patel NB, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis: from anecdote to translational medicine. Benef Microbes. 2013;25:1–15.Google Scholar
  35. 35.
    Ludvigsson JF, Montgomery SM, Ekbom A. Risk of pancreatitis in 14,000 individuals with celiac disease. Clin Gastroenterol Hepatol. 2007;5(11):1347–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Sadr-Azodi O, Sanders DS, Murray JA, Ludvigsson JF. Patients with celiac disease have an increased risk for pancreatitis. Clin Gastroenterol Hepatol. 2012;10(10):1136–42 e3.Google Scholar
  37. 37.
    Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut. 2005;54(1):54–9.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Ciacci C, Cirillo M, Sollazzo R, Savino G, Sabbatini F, Mazzacca G. Gender and clinical presentation in adult celiac disease. Scand J Gastroenterol. 1995;30(11):1077–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology. 2005;128(4 Suppl 1):S68–73.PubMedCrossRefGoogle Scholar
  40. 40.
    Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Benjamin Lebwohl
    • 1
    • 2
  • Anders Sundström
    • 3
  • Bana Jabri
    • 4
  • Sonia S. Kupfer
    • 4
  • Peter H. R. Green
    • 1
  • Jonas F. Ludvigsson
    • 2
    • 5
  1. 1.Celiac Disease Center, Department of MedicineColumbia University College of Physicians and SurgeonsNew YorkUSA
  2. 2.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
  3. 3.Clinical Epidemiology UnitKarolinska InstitutetStockholmSweden
  4. 4.Celiac Disease CenterUniversity of ChicagoChicagoUSA
  5. 5.Department of PaediatricsÖrebro University HospitalÖrebroSweden

Personalised recommendations